Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 2, 2019
- Accepted in final form March 23, 2020
- First Published August 5, 2020.
Article Versions
- Previous version (August 5, 2020 - 12:46).
- You are viewing the most recent version of this article.
Author Disclosures
- Julie Gonneaud, PhD,
- Christophe Bedetti, MSc,
- Alexa Pichet Binette, MSc,
- Tammie L.S. Benzinger, MD, PhD,
- John C. Morris, MD,
- Randall J. Bateman, MD,
- Judes Poirier, PhD, MD (Hon),
- John C.S. Breitner, MD, MPH,
- Sylvia Villeneuve, PhD;
- for the DIAN Study Group and the PREVENT-AD Research Group
- Julie Gonneaud, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christophe Bedetti, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alexa Pichet Binette, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tammie L.S. Benzinger, MD, PhD,
(1) Advisory board, Eisai
NONE
(1) Radiologic Society of North America, travel to grant review (2) Alzheimer's Association International Convention (AAIC) 2017, 2018, 2019, 2020 travel (invited speaker)
NONE
NONE
NONE
NONE
Unpaid consulting, ADMDx, Siemens, Eli Lilly, Eisai.
Biogen
NONE
NONE
(1) Investigator initiated research grants, Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). Support for the research projects only, no personal compensation or salary support. (2) Roche - participation as site investigator in clinical trials (3) Biogen - participation as site investigator in clinical trials (4) J&J - participation as site investigator in clinical trials (5) Lilly - participation as site investigator in clinical trials (7) Eisai- participation as site investigator in clinical trials
(1) NIH funded research
NONE
(1) Barnes-Jewish Hospital Foundation (2) Foundation for the ASNR (3) Hope Center (4) Alzheimer's Association
NONE
NONE
NONE
NONE
NONE
NONE
- John C. Morris, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institute on Aging grants P50AG005681; P01AG003991; P01AG026276; UF1AG032438
NONE
NONE
NONE
1. Clinical Dementia Rating assessment tool (pharma-sponsored clinical trials of investigational drugs for Alzheimer disease 2. AD8 assessment tool (pharma-sponsored clinical trials of investigational drugs for Alzheimer disease)
NONE
NONE
NONE
NONE
- Randall J. Bateman, MD,
(1) C2N Diagnostics, present (2) World Dementia Council, 2018
NONE
(1) Salk Institute for Biological Studies - Adler Meeting - travel. (2) Rainwater Foundation - Tau Consortium - travel (3) Alzheimer's Association - travel (4) Roche - travel and honoraria (5) AC Immune - travel and honoraria (6) American Neurological Association - travel (7) Eisai - honoraria
(1) The Journal for the Prevention of Alzheimer Disease, Editorial Board 2014-present
(1)Holtzman, DM, Bateman, RJ, Kim, J, inventors; Washington University in St. Louis, assignee. Methods for measuring the metabolism of CNS derived biomolecules in vivo. US Patent Application 12/267,974. June 4, 2009. (2)Bateman, RJ, Holtzman, DM, inventors; The Washington University, assignee. Fluctuations in Amyloid Beta as a Biomarker for AlzheimerÂs Disease. US Patent Application PCT/US2008/086529. June 18, 2009. (3) Bateman, RJ, Wildsmith, KR, Dobrowolska, J, Munsell, L,Mawuenyega, K, inventors; The Washington University, assignee. Methods for simultaneously measuring the in vivo metabolism of two or more isoforms of a biomolecule. US Patent Application PCT/US2009/064146. May 20, 2010. US Patent Application 13/129,036. December 1, 2011. (4) Bateman, RJ, Holtzman, DM, inventors; The Washington University, assignee. Methods for Measuring the Metabolism of Neurally Derived Biomolecules in Vivo. US Patent 7,892,845. October 2, 2008. US Patent 8,232,107. July 31, 2012 US Patent Application 14/224,993. July 17, 2014. (5) Bateman, RJ, Holtzman, DM, Mawuenyega, K, inventors; The Washington University, assignee. Methods of determining amyloid beta turnover in blood. US Patent Application PCT/US2011/037754. June 26, 2012. US Patent Application 13/699,497. May 9, 2013. (6) Bateman, RJ, Mawuenyega, K, Ovod, V, Bareiss, A, Kasten, T, Holtzman, DM, inventors; The Washington University, assignee. Methods for Detecting Amyloid Beta Amyloidosis. US Patent Application PCT/US2016/0178646. US Patent Application 15/057,694. June 23, 2016 (7)Bateman, RJ, Patterson, BW, Elbert, DL, inventors; Washington University, assignee. Methods of Diagnosing Amyloid Pathologies Using Analysis of Amyloid-Beta Enrichment Kinetics. US Patent Application PCT/US2013/071042. May 30, 2014. (8) Bateman, RJ, inventor; Washington University, assignee. Plasma Based Methods for Detecting CNS Amyloid Deposition. US Patent Application 62/492,718. May 1, 2017. US Patent Application 62/515,294. June 5, 2017.
NONE
(1) Washington University School of Medicine Charles F. and Joanne Knight Distinguished Professor of Neurology, 2012-present (2) A4, Site Principal Investigator, 2014 to present (3) Washington University School of Medicine, Professor of Neurology, 2015 (4) Dominantly Inherited AlzheimerÂs Network Trials Unit (DIAN-TU), Director, 2011-Present (5) Dominantly Inherited Alzheimer's Network (DIAN), Director, 2013-present
(1) Roche (2) AC Immmune (3) Eisai
NONE
NONE
NONE
(1) Eli Lilly (2) Roche (3) Janssen (4) DIAN Pharmaceutical Consortium (Biogen, Eisai, Lilly/Avid, Roche/Genentech, United Neuroscience, Janssen) (5) Abbvie (6) Avid (7) Biogen
(1) NIH R01AG053798, Advisor, 2017-present (2) NIH R01NS095773, PI, 2016-present (3) NIH/NIA U01AG042791, PI, 2013-present (4) NIH/NIA R01AG046179, PI, 2014-present (5) NIH/NIA UF1AG032438, PI, 2008-present (6) NIH R01AG053267, PI, 2017-present (7) NIH U19AG010483, Site PI, 2012-present (8) NIH R01AG061900(R01NS065667), PI, 2008-present (9) NIH U01AG059798, Co-Investigator, 2018-present
NONE
(1) BrightFocus Foundation (2) Cure Alzheimer's Fund (3) Association for Frontotemporal Degeneration (4) Rainwater Foundation (5) Alzheimer's Association (6) GHR Foundation (7) Anonymous Foundation
C2N Diagnostics
C2N Diagnostics, Washington University
C2N Diagnostics, Washington University
NONE
NONE
NONE
- Judes Poirier, PhD, MD (Hon),
1) Fondation Alzheimer (France)
NONE
1) NYU, Speaker, Symposium on Alzheimer, honorarium.
Journal of Alzheimer's Disease, Associate Editor, 2017- 2019
NONE
Young and Centanarian, Trécarré (Canada), 2017 Alzheimer's Disease: The Complete Guide, 2012 La Maladie d'Alzheimer : Trécarré, (Canada), 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
J.L. Levesque Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- John C.S. Breitner, MD, MPH,
(1) Mayo Clinic Studies on Aging, Scientific Advisory Board(NIH-funded program)(2) Data and Safety Monitoring Board, SPRINT-MIND clinicaltrial (NIA / NHLBI sponsor)(3) Chair, DSMB, for MTI biotech Phase 1 trial
NONE
Receive occasional honoraria for industry-sponsored talks
Alzheimer's Disease and Associated Disorders, EditorialBoard, 2003 - present;PLOS-One, Academics, 2009 - present;Alzheimer's and Dementia, Editorial Board, 2007 - present;
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research Support (gift) from Pfizer Canada
(1) Fonds de Recherche du Quebec - SantePI 2012-2015CIHR 2019-
(1) Program support from McGill University Faculty of Medicine
(2) Research support from the Douglas Hospital Research Centre and the Douglas Hospital Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Sylvia Villeneuve, PhD;
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Canadian Institutes of Health Research, post-doctoral fellowship, 02/12 to 01/15
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- for the DIAN Study Group and the PREVENT-AD Research Group
- From the Department of Psychiatry (J.G., C.B., A.P.B., J.P., J.C.S.B., S.V.), McGill University; Douglas Mental Health University Institute (J.G., C.B., A.P.B., J.P., J.C.S.B., S.V.), StoP-AD Centre, Montreal, Canada; Knight Alzheimer's Disease Research Center (T.L.S.B., J.C.M., R.J.B.); and Washington University School of Medicine (T.L.S.B., J.C.M., R.J.B.), St. Louis, MO.
- Correspondence
Dr. Villeneuve sylvia.villeneuve{at}mcgill.ca or Dr. Gonneaud julie.gonneaud{at}mail.mcgill.ca
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Symptom onset in autosomal dominant Alzheimer diseaseA systematic review and meta-analysisDavis C. Ryman, Natalia Acosta-Baena, Paul S. Aisen et al.Neurology, June 13, 2014 -
Article
Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PETRenaud La Joie, Adrienne V. Visani, Orit H. Lesman-Segev et al.Neurology, December 01, 2020 -
Article
Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer diseaseFen Wang, Brian A. Gordon, Davis C. Ryman et al.Neurology, August 05, 2015 -
Article
Impaired default network functional connectivity in autosomal dominant Alzheimer diseaseJasmeer P. Chhatwal, Aaron P. Schultz, Keith Johnson et al.Neurology, July 24, 2013